Neumedicines Inc. is a privately held biotechnology company developing protein therapeutics that address unmet clinical and societal needs in the areas of Oncology, Hematology and Immunology.
NMIL12-1 (recombinant human interleukin-12 or rHuIL-12), the company’s lead product in development, targets multiple pathways of hematopoiesis and innate immunity and is being developed to address a broad range of clinical indications.
At Neumedicines, we are committed to developing and maximizing the scientific, clinical, and commercial potential of our product pipeline.
Bringing information and resources to you where you are looking for them is important to us. Please follow us on Twitter (@Neumedicines
) to keep up to date on the latest Neumedicines news and developments.